PMC9468777_01
Changes in serum bevacizumab concentration and clinical course of the patient. (A) Changes in serum bevacizumab concentration at five time points after treatment initiation. (B) Clinical course of the patient. Red and yellow circles represent lung and liver metastases, respectively.
fonc-12-947013-g001.jpg
PMC9468777_01_fonc-12-947013-g001.jpg
f1
It was observed that the serum concentration of bevacizumab increased to 56.3 microg/mL on day 2 but then decreased over time regardless of hemodialysis; the serum concentration on day 8 decreased to 37.1 microg/mL ( Figure 1A ). Thereafter, the disease showed progression with elevated tumor markers and increased size and number of lung and liver metastases ( Figure 1B ), following which the treatment regimen was changed to trifluridine/tipiracil.